New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - voriconazole 200mg;  ;   - film coated tablet - 200 mg - active: voriconazole 200mg     excipient: croscarmellose sodium lactose monohydrate magnesium stearate opadry white oy-ls-28914 povidone pregelatinised maize starch purified water   - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - voriconazole 50mg;  ;   - film coated tablet - 50 mg - active: voriconazole 50mg     excipient: croscarmellose sodium lactose monohydrate magnesium stearate opadry white oy-ls-28914 povidone pregelatinised maize starch purified water   - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - voriconazole 200mg;  ;   - powder for injection - 200 mg - active: voriconazole 200mg     excipient: sulfobutyl betadex sodium water for injection - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - voriconazole 40 mg/ml;  ;   - powder for oral suspension - 40 mg/ml - active: voriconazole 40 mg/ml     excipient: citric acid colloidal silicon dioxide orange flavour 57458 ap05514 sodium benzoate sodium citrate dihydrate sucrose titanium dioxide xanthan gum - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - axitinib 1mg;   - film coated tablet - 1 mg - active: axitinib 1mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry red 32k15441 - treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - axitinib 5mg;   - film coated tablet - 5 mg - active: axitinib 5mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry red 32k15441 - treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - azithromycin dihydrate 262mg equivalent to 250 mg azithromycin;  ;   - film coated tablet - 250 mg - active: azithromycin dihydrate 262mg equivalent to 250 mg azithromycin     excipient: calcium hydrogen phosphate croscarmellose sodium magnesium stearate opadry white y-30-18037 pregelatinised maize starch purified water  

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - azithromycin dihydrate 524mg equivalent to 500 mg azithromycin;  ;   - film coated tablet - 500 mg - active: azithromycin dihydrate 524mg equivalent to 500 mg azithromycin     excipient: calcium hydrogen phosphate croscarmellose sodium magnesium stearate/sodium lauryl sulfate 90/10 blend opadry white y-30-18037 pregelatinised maize starch purified water  

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - azithromycin dihydrate 628.93mg equivalent to 600 mg azithromycin;  ;   - film coated tablet - 600 mg - active: azithromycin dihydrate 628.93mg equivalent to 600 mg azithromycin     excipient: calcium phosphate croscarmellose sodium magnesium stearate opadry white y-30-18037 sodium laurilsulfate starch

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - azithromycin dihydrate 40 mg/g;  ;   - powder for oral suspension - 200 mg/5ml - active: azithromycin dihydrate 40 mg/g     excipient: ar crema vaniglia (vanilla) n11489 (sc613737) flavour aroma ciliegia (cherry) n11929 (10805307) flavour banana flavour n15223 (10805500) hyprolose sodium phosphate, tribasic sucrose xanthan gum